MetaCap

ADARx Pharmaceuticals (ADRX) vs Rapport Therapeutics (RAPP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ADARx Pharmaceuticals is the larger company by market cap ($1.42 billion vs $1.37 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADRX-33.90%RAPP-31.70%
+9%-14%-36%
Sep 25, 20261 yearNov 20, 2026
ADRX-33.90%RAPP-31.70%
+2%-17%-36%
Sep 21, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADRX versus RAPP key metrics
MetricADRXRAPP
Share price$12.79$23.16
Market cap$1.42B$1.37B
1-day change-9.68%-1.82%
YTD return—-23.67%
1-year return—-15.01%
EPS (TTM)$-6.75$-3.17
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)—$-111.48M
52-week high$23.21$52.93
52-week low$12.50$22.06
Distance from 52-week high-44.89%-56.24%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+167.79%+177.25%
Average volume650.63K790.62K
Shares outstanding111.19M59.28M
Employees10084
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About ADARx Pharmaceuticals

ADRX stock →

ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Rapport Therapeutics

RAPP stock →

Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees

ADRX vs RAPP FAQ

Which is bigger, ADARx Pharmaceuticals or Rapport Therapeutics?

ADARx Pharmaceuticals (ADRX) is larger, with a market capitalization of $1.42B compared with $1.37B for Rapport Therapeutics (RAPP).

Are ADARx Pharmaceuticals and Rapport Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons